Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19FN4O5S |
| Molecular Weight | 410.42 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)C(O)=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(F)C=C3
InChI
InChIKey=VNIWZCGZPBJWBI-UHFFFAOYSA-N
InChI=1S/C17H19FN4O5S/c1-21-16(25)14(23)13(15(24)19-10-11-4-6-12(18)7-5-11)20-17(21)22-8-2-3-9-28(22,26)27/h4-7,23H,2-3,8-10H2,1H3,(H,19,24)
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.selleckchem.com/products/BMS-707035.html
Curator's Comment: Description was created based on several sources, including
http://www.selleckchem.com/products/BMS-707035.html
BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity. Bristol-Myers Squibb was developing BMS-707035 for the treatment of HIV infections, however development was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID601025869
Created by
admin on Sat Dec 16 11:11:44 GMT 2023 , Edited by admin on Sat Dec 16 11:11:44 GMT 2023
|
PRIMARY | |||
|
54682040
Created by
admin on Sat Dec 16 11:11:44 GMT 2023 , Edited by admin on Sat Dec 16 11:11:44 GMT 2023
|
PRIMARY | |||
|
7PR4P7YOKT
Created by
admin on Sat Dec 16 11:11:44 GMT 2023 , Edited by admin on Sat Dec 16 11:11:44 GMT 2023
|
PRIMARY | |||
|
729607-74-3
Created by
admin on Sat Dec 16 11:11:44 GMT 2023 , Edited by admin on Sat Dec 16 11:11:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
